These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30890272)

  • 1. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of
    Carson P; Cade A
    Pharm Pat Anal; 2019 May; 8(3):65-70. PubMed ID: 31179899
    [No Abstract]   [Full Text] [Related]  

  • 3. 'Follow-on biologics': ensuring continued innovation in the biotechnology industry.
    Manheim BS; Granahan P; Dow KJ
    Health Aff (Millwood); 2006; 25(2):394-404. PubMed ID: 16610097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

  • 5. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
    Darrow JJ; Beall RF; Kesselheim AS
    Appl Health Econ Health Policy; 2019 Feb; 17(1):47-54. PubMed ID: 30141133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotech reels over patent ruling.
    Check-Hayden E
    Nature; 2014 Jul; 511(7508):138. PubMed ID: 25008505
    [No Abstract]   [Full Text] [Related]  

  • 8. Bilski blundering biotech.
    Simmons WJ
    Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
    [No Abstract]   [Full Text] [Related]  

  • 9. Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance.
    Kennedy DC
    Duke Law J; 2019 Apr; 68(7):1433-68. PubMed ID: 30995705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape.
    Lu DL; Kowalski TJ; Jarecki-Black J
    Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040
    [No Abstract]   [Full Text] [Related]  

  • 12. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 13. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 14. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hatch-waxman changes debated.
    Chahine K
    Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
    [No Abstract]   [Full Text] [Related]  

  • 16. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical patent challenges--time for reassessment?
    Glass G
    Nat Rev Drug Discov; 2004 Dec; 3(12):1057-62. PubMed ID: 15573104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Court upholds infringement of research tool patents, but discounts damages.
    Maebius SB; Warburg RJ
    Pharmacogenomics; 2003 Jul; 4(4):369-70. PubMed ID: 12831314
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotechnology patent disputes. Market machinations.
    Gershon D
    Nature; 1990 Apr; 344(6269):800. PubMed ID: 2330035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.